Eric Rowinsky, MD

Clinical Development

Eric Rowinsky, MD

Clinical Development

Eric Rowinsky, MD

Clinical Development

Eric Rowinsky, MD

Clinical Development

Eric Rowinsky, MD

Clinical Development

Biography

Eric K. Rowinsky, MD brings over 30 years of extensive oncology and corporate strategy expertise, research and drug development experience, and broad scientific and medical knowledge to the Radyus Research Advisory Board.

Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Editorial Board Member of Cancer Research and several other oncology journals and has published approximately 315 manuscripts in both the nonclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of many pharmaceutical and biotechnology companies, as well investor groups, and has advised and/or presented aspects of NDAs to the FDA on many occasions. Since 2015, Dr. Rowinsky has served as an Executive Director and President at Rgenix Inc., a life sciences company focused on discovering new cancer targets using a novel microRNA platform, as well as the Chief Scientific Officer of ClearPath Development Co., which rapidly advances development stage therapeutic assets to pre-defined human Proof-of-Concept milestones.  Dr. Rowinsky served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio where he held the SBC Endowed Chair for Early Drug Development and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents, some of which led to the registration of these products in various indications. Dr. Rowinsky received his BA degree from New York University and his MD from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine.

Work History

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Education

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

My passion is centered around the comprehensive development and registration strategies of cancer therapeutics.